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Redundancy of autocrine loops in human rhabdomyosarcoma cells:
induction of differentiation by suramin
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Smmay Three human rhabdomyosarcoma cell lines were used to investigate the presence of autocrine loops
based on the production of insulin-like growth factor (IGF)-II, basic fibroblast growth factor (bFGF) and
epidermal growth factor (EGF)jtransforming growth factor (TGF)-a and of their corresponding receptors, and
whether these loops affect cell proliferation and myogenic differentiation. Two cell lines, RD/18 and CCA,
deriving from tumours of the embryonal histotype, showed the presence of both growth factors and receptors
which make possible three different autocrine loops, while the alveolar RMZ-RC2 cell line lacked that based
on the EGF receptor. Culture of rhabdomyosarcoma cells in the presence of specific blocking antibodies,
directed to a component of single autocrine loops, inhibited cell proliferation (up to 50%), without inducing
myogenic differentiation. Suramin. a drug which non-selectively interferes with the binding of growth factors
to their cellular receptors, was used to block all the autocrnne loops simultaneously. In CCA and RMZ-RC2
cells suramin was able to induce a significant increase (up to 3-fold) in the proportion of myosin-positive cells
over control cultures. Therefore rhabdomyosarcoma cells of embryonal and alveolar histotype can show a
redundancy ofgrowth-sustaining autocrine loops. Suramin could interfere with them by acting on both growth
inhibition and induction of myogenic differentiation.
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Rhabdomyosarcoma. a tumour of the skeletal muscle which
can retain myogenic differentiative ability in vitro (Garvin et
al., 1986; Nanni et al., 1986; Gabbert et al., 1988; Aguanno
et al., 1990), is a suitable model to study autocrine loops
involved in proliferation and or differentiation of solid
tumours, and to set up a differentiation therapy approach
(Waxman et al., 1991) based on the blockade of autocrine
loops. Normal muscle cells can be driven to proliferate or
differentiate by a balance of opposing cellular signals (Florini
and Magri, 1989; Olson, 1992). Among them, growth factors
can have intriguing effects: epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF) and transforming
growth factor (TGF)-p are inhibitors of myogenic differentia-
tion, even when used under non-mitogenic conditions, while
insulin-like growth factors (IGFs) can either inhibit or
stimulate myogenic differentiation depending on growth fac-
tor dosage (Florini and Magri, 1989; Olson, 1992) and exp-
ression level of receptor (Quinn et al., 1993). Autocrine
growth factor loops can be expressed by rhabdomyosarcoma
cells: bFGF (Schweigerer et al., 1987) and IGF-II (El-Badry
et al., 1990; Minniti et al., 1992) are likely to be involved in
the growth of these cells in vitro, but data on their possible
role in the control of differentiation of myogenic neoplastic
cells are still lacking. In this paper we report on the simul-
taneous production of different growth factors (IGF-II,
bFGF, EGF, TGF-a) and receptors by human rhab-
domyosarcoma cell lines. The effects exerted on proliferation
and differentiation by antibodies directed to single autocrine
loops were compared with those induced by suramin, a drug
which non-selectively interferes with the binding to cellular
receptors by heparin-binding growth factors as well as by
other growth factors like EGF (Stein, 1993; Sachsenmaier et
al., 1994) and therefore is expected to block all the autocrine
circuits simultaneously.
Materials and meds
Cells and culture conditions
Human rhabdomyosarcoma cell lines used were RD/18 and
CCA, derived from tumours of the embryonal histotype (De
Giovanni et al., 1989, 1993), and RMZ-RC2, derived from
an alveolar rhabdomyosarcoma (Nanni et al., 1986). Cells
were routinely cultured in Dulbecco's modified Eagle
medium (DMEM) + 10% fetal calf serum (FCS) at 37'C in
7% carbon dioxide atmosphere in 25 cm2 flasks (NUNC,
Denmark).
Growthfactor and receptors
The mRNA for growth factors and receptors expressed by
rhabdomyosarcoma cells were evaluated by reverse transcrip-
tase-polymerase chain reaction (RT-PCR). Total cellular
RNA was isolated by the guanidine isothiocyanate method
and cDNA obtained by using M-MLV reverse transcriptase
(Gibco, Gaithersburg, MD, USA) in the presence ofoligo-dT
and dNTP. RT-PCR reactions with primer pair for A2-
microglobulin and glyceraldehyde-3-phosphate-dehydrogen-
ase (Clontech, Palo Alto, CA, USA) were performed for 20,
25 and 30 cycles to find out the exponential phase to allow a
semiquantitative comparison among the cDNA developed
from identical RT reactions. Specific primer pairs for growth
factors and receptors were obtained from Clontech or
designed and synthesised in our laboratory as reported
elsewhere (Mattei et al., 1994). The following primers were
used to amplify a 319 bp long fragment of IGF-II: direct
5'-CGTGCTGCATTGCTGCTTACC-3' (position 309-329);
reverse 5'-AGGCGCTGGGTGGACTGCTT-3' (position
627-608) (Bell et al., 1984). Expression of specific membrane
receptors was determined by indirect immunofluorescence
and cytofluorimetric analysis (FACScan, Becton Dickinson,
Mountain View, CA, USA), using primary monoclonal
antibodies a-IR3 and clone 528 directed against IGF-I recep-
tor and EGF receptor respectively (see below), and VBSI
recognising the human bFGF receptor (Santa Cruz Biotech-
nology, CA, USA). The results shown are from an experi-
ment representative of three.
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Blocking antibodies
Monoclonal antibody cx-IR3 against the IGF-I receptor was
purchased from Oncogene Science (Uniondale, NY, USA); it
was used at 1-1.5tig ml-'. concentrations that had proved
to be optimal for the antiproliferative effect in a closely
related model with RD cells releasing up to 200 ng ml-'
IGF-II (El-Badry et al., 1990). Monoclonal antibody 528
against the EGF receptor was purchased from Oncogene
Science; it is reported to maximally inhibit at 3 n-M the
proliferation of A431 epidermoid carcinoma cells, highly res-
ponsive to EGF (Kawamoto et al., 1983). In the present
study it was used at 1.5 xg ml-' (about 10 nM). Rabbit
antiserum against bFGF was kindly provided by P Mignatti
(University of Pavia, Italy; Mignatti et al., 1991) and used at
1:67-1:100 dilution. a concentration that can neutralise up
to 10ng ml' bFGF (P Mignatti, personal communication).
Concentrations of antibodies were the same for all the lines
since only minor quantitative variations in the expression
level of receptors were found among cell lines (except for the
absolute lack of EGF receptor in RMZ-RC2).
Proliferation and differentiation experiments
To study the effects of the blockade of single autocrine
circuits, cells were seeded in 24-well Costar plates (cells per
well: RD 18. 20000: CCA and RC2, 100 000). After 24 h
culture medium was shifted to DMEM + 2% horse serum
(HS) with or without (control) blocking antibody. The 2%
HS medium is used in rhabdomyosarcoma cell cultures as a
differentiation-inducing medium (Lollini et al., 1989) and
should allow a better recognition of the role played by
autocrine loops owing to the lower content of exogenous
growth factors in comparison with standard culture medium
supplemented with 10% FCS. The effect on proliferation was
evaluated on harvested cultures by cell count, and data were
expressed as percentage of control cell yield. Rhabdomyosar-
coma cells cultured in differentiation medium give rise to a
fraction of differentiated myosin-positive elements that in-
creases with time, reaching a maximal level after about
10-15 days of culture (Lollini et al., 1989). To study the
effect on differentiation, cultures were carried out as des-
cnbed for about 2 weeks, with medium renewal (with or
without antibody) every 2-3 days. At 3-4 day intervals, cells
were harvested, counted and cytocentrifuge slides prepared.
The percentage of myosin-positive cells was determined after
staining with monoclonal antibody BF-G6 (kindly provided
by S Schiaffino, University of Padova), reacting with the
embryonic myosin heavy chain (Nanni et al., 1986). In some
experiments, the effect of suramin was evaluated as above.
Suramin (FBA, Bayer. Germany), kindly provided by M
Rusnati. Umiversity of Brescia, Italy, was added to cultures
starting 1 day after seeding in DMEM + 2% HS. Medium
with or without suramin was changed every 2-3 days.
Results
Autocrine growthfactor production
The presence of autocrine growth factor circuits in three
rhabdomyosarcoma cell lines was studied by means of
RT-PCR; when possible. specificity of the product was
assayed also by specific antibodies and cytofluorimetric
analysis. All the cell lines (Figure 1) showed a high level of
IGF-II mRNA and the presence of membrane IGF-I recep-
tor (which is known to bind IGF-II as well), suggesting an
IGF-II-induced growth stimulation. The IGF-II RT-PCR
product was detectable after 15 cycles of amplification,
whereas 1-microglobulin required 20 cycles to be detectable
(data not shown). In addition, all the cell lines expressed
both bFGF mRNA and its specific receptor, whereas the
autocrine circuit based on EGF and TGF-a. both interacting
with EGF-receptor, showed a more restricted pattern. In
fact, the RMZ-RC2 cell line expressed EGF mRNA but
lacked both TGF-z mRNA and EGF receptor. The primers
used for TGF-a gave rise to some non-specific bands, how-
ever none had exactly the expected size, thus on the basis of
four independent RT-PCR experiments it was concluded
that TGF-a mRNA was not present in RMZ-RC2 cells.
Inhibition with antibodies
Specific antibodies were used to block each autocrine loop
and test its relevance in sustaining in vitro cell proliferation.
Figure 2 shows the growth inhibition of all the cell lines at
the same time point (4 days). In some cases slightly higher
inhibitions were obtained at different time points (compare
Figure 2 with insets of Figure 3). The IGF-I receptor plays a
relevant role on rhabdomyosarcoma cell growth. since inhibi-
tions of 30-50% were obtained with the antibody directed to
IGF-I receptor. Growth inhibition by antibody neutralising
bFGF was 40% for RD 18 cells and 10% for CCA and
RMZ-RC2 cells. A slight inhibition was observed in RD'18
and in CCA cells in the presence of antibody to EGF recep-
tor, while RMZ-RC2 cells remained almost unaffected
because they lack the EGF receptor. Growth inhibition
induced by antibodies was due to a cytostatic rather than
cytotoxic effect, since no effect on cell viability was observed
throughout the experiment (data not shown). Inhibition was
obtained by either a monoclonal antibody (anti-IGF-I recep-
tor) and by a polyclonal antiserum (anti-bFGF). suggesting
that both sources could be adequate to gain an anti-
proliferative effect. Concerning the specificity of effects
observed, cx-IR3 moncolonal antibody is reported to
specifically block IGF-I receptor in a closely related model
(El-Badry et al.. 1990), and monoclonal antibody 528 was









Fiwe 2 Inhibition of rhabdomyosarcoma cell proliferation by
antibodies to components of single autocrine circuits. Cell yield
was evaluated after 4 days of culture: results are expressed as
percentage of growth inhibition in comparison with cells without
antibody and kept under the same culture conditions. Mean +
standard error of three experiments is shown. _, RD 18;
,, CCA; =O RC2.
Fige 1 Expression of growth factors and receptors in human rhabdomyosarcoma cell lines. (a) Ethidium bromide-stained
agarose gels loaded with 8 LI from RT-PCR reaction (P2-microglobuhn, 30 amplification cycles; growth factors and receptors, 40
cycles). Amplification products for the three cell lines were from simultaneous sets of RT-PCR reactions and were run on the same
agarose gel. (b) Membrane expression of IGF-I receptor (IGF-I R), bFGF receptor (bFGFR) and EGF receptor (EGFR)
determined by cytofluonrmetric analysis. Mean fluorescence in arbitrary units is shown.Acrine cirus in humn rabdnubarM cells
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Figure 3 Effect on myogemnc differentiation of RD 18 cells by
treatment with antibodies blocking IGF-I receptor (top), bFGF
(centre) and EGF receptor (bottom): 0, No treatment; *,
antibody. The insets show the percentage of cell growth inhibi-
tion induced by the antibody treatments. Different antibodies
were tested in separate experiments. Data from an experiment
representative of two similar experiments are shown for each
antibody.
negative RMZ-RC2 cell line (Figure 2). Specificity of the
inhibition obtained with polyclonal anti-bFGF rabbit
antiserum was assessed by running in parallel samples with
non-immune rabbit serum: no effect on proliferation was
observed (data not shown).
The simultaneous use of the three antibodies did not dem-
onstrate additive effects, thus suggesting a redundancy of
growth-stimulatory pathways (data not shown).
Differentiation therapy ofrhabdomyosarcoma
Growth factors may antagonise myogenic differentiation,
thus we studied whether the interruption of growth factor-
based autocrine loops might enhance myogenic
differentiation of rhabdomyosarcoma cells. Blockade of sin-
gle autocrine circuits with antibodies blocking IGF-I recep-
tor, bFGF or EGF receptor did not increase myogenic
differentiation over control cultures in RD/18 cells (Figure 3)
as well as in the two other rhabdomyosarcoma cell lines
(data not shown). It should be noted also that the simul-
taneous treatment with the three antibodies failed to
significantly induce myogenic differentiation of rhab-
domyosarcoma cells (data not shown).
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- Figre 4 Effect of suramin on proliferation (a) and on myogenic
15 differentiation (b) of human rhabdomyosarcoma cells. Data from
an experiment representative of two similar experiments are exp-
ressed as percentage of control.




Cell line Control (1(X p.g ml-) (paired t-test)
RD, 18 20.9 3.4 24.7 3.5 NS
CCA 10.9± 1.7 31.9 6.3 P<0.05
RMZ-RC2 10.8 ± 2.6 17.6 ± 3.6 P<0.05
'Mean ± standard error of four independent experiments. Myosin
positivity was evaluated after a 10 day culture. NS, not significant.
If multiple autocrine loops are likely to control both rhab-
domyosarcoma growth and differentiation (including some
not addressed in the present work), the simultaneous block-
ing of all the circuits possibly obtained by suramin might
result in a better effect. In addition to the blocking of cell
proliferation in CCA and RMZ-RC2 cells lines suramin, at
the highest doses given, significantly increased the percentage
of myogenic differentiated elements over untreated cells
(Figure 4 and Table I). RD/18 cells proved to be five times
less sensitive than CCA and RMZ-RC2 to the antip-
roliferative action of suramin, and their differentiation was
not stimulated.
Diomss
We found that human rhabdomyosarcoma cells can show a
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The three rhabdomyosarcoma cell lines showed a very high
level of IGF-II mRNA. in agreement with the high level of
IGF-II protein reported to be present in supernatants of the
RD cell line (El-Badry et al.. 1990). from which the RD 18
clone had been derived (De Giovanni et al.. 1993). Moreover.
the three cell lines showed a high and comparable expression
of IGF-I receptor. In normal myogenic cells IGF-II is prob-
ably the most important growth factor inducing both growth
and differentiation (Florini and Magri; 1989. Olson. 1992). It
is produced in all rhabdomyosarcoma tumours (Yun, 1992;
Minniti et al., 1994) and plays a role in rhabdomyosarcoma
cell proliferation (Kalebic et al.. 1994; Shapiro et al.. 1994).
However, under particular conditions (high IGF-II doses or
receptor overexpression) it could also inhibit myogenic
differentiation (Florini and Magri. 1989; Quinn et al.. 1993).
We therefore analysed whether the blockade of this loop
affects rhabdomyosarcoma cells. Cell proliferation was
indeed inhibited but differentiation followed the same kinetics
of control cultures and reached similar levels.
The two other possible autocnrne loops showed some
differences among cell lines. bFGF mRNA and FGF-
receptor were present in all the rhabdomyosarcoma lines
studied, but only RD 18 cells showed a substantial growth
inhibition after treatment with blocking antibody. The circuit
based on the production of EGF TGF-a and of the common
EGF receptor was absent in the RMZ-RC2 cell line, which
did not express EGF receptor and TGF-a mRNA and was
not affected by the presence of the anti-EGF receptor block-
ing antibody. The lack of EGF receptor could be related to
its origin from the alveolar histotype. Treatment with
antibodies to components of either bFGF or EGF TGF-a
autocrine loops did not result in an increase in myogenic
differentiation.
From these observations it can be concluded that in the
human rhabdomyosarcoma model a decrease in cell growth
is not per se sufficient to trigger myogenic differentiation.
This conclusion is in agreement with findings obtained using
drugs and other pharmacological treatments (Lollini et al..
1989; De Giovanni et al., 1993).
Multiple autocrine circuits with inhibitory activity might
simultaneously operate in the same cell. In order to obtain a
simultaneous block of all the autocrine circuits, we tested the
effect of suramin. a molecule which non-selectively interferes
with the binding of growth factors to their cellular receptors
(Stein, 1993; Sachsenmaier et al., 1994). It has been found
effective in inhibiting rhabdomyosarcoma proliferation (Min-
niti et al.. 1992; Kalebic et al., 1994), but no data on
differentiation were available so far. In our system suramin
caused a marked growth inhibition of CCA and RMZ-RC2
cells and significantly increased the percentage of myosin-
positive cells.
In contrast RD 18 cells displayed an entirely different
behaviour: the dose of suramin required for 50% growth
inhibition was about five times higher. and no induction of
myogenic differentiation was obtained at any suramin dose.
These results suggest the existence of two different
mechanisms in the response of rhabdomyosarcoma cells to
suranmn: a high affinity pathway, which mediates both
growth inhibition and myogenic differentiation, as in CCA
and RMZ-RC2. and a low affinity one which entails only
growth inhibition. as in RD 18.
On the whole our results with blocking antibodies indicate
that the effects of suramin on myogenic differentiation are
not mediated by IGF-II. bFGF, or EGF TGF-a. An obvious
possibility would be the existence of additional autocrine
loops. but it must be taken into account also that suramin
has pleiotropic effects. not limited to the interaction between
growth factors and their receptors. but extended to other
metabolic pathways (Stein. 1993). Among these, the inhibi-
tion of protein kinase C (PKC) activity could be important in
the myogenic system. PKC plays a role in the transduction of
growth factor signals and seems to be crucial in the signal
transduction pathways that inhibit myogenesis. Activated
PKC can mimic the effect of FGF on the inhibition of
muscle-specific gene activation (Li et al.. 1992). Suramin can
also inhibit topoisomerase II (Stein. 1993). a pathway
blockade shared with many antineoplastic drugs. We showed
some years ago that some antimeoplastic drugs can indeed
stimulate myogenic differentiation of rhabdomyosarcoma
(Lollini et al.. 1989).
The use of suramin in preclinical studies led to some
evidence of differentiation induction in other human
tumours. such as colorectal cancer (Baghdiguian et al.. 1992:
Stein, 1993: Lahm et al.. 1994) and hepatoma cells (Kraft et
al.. 1993). Induction of differentiation by suramin has also
been reported in a dimethylbenzanthracene-induced rat rhab-
domyosarcoma (Arnold and Salminen. 1993). Our results
suggest that suramin could hamper the growth of human
rhabdomyosarcoma cells and favour their myogenic
differentiation.
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